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Abstract
Background: Surgery in patients with obstructive jaundice caused by a periampullary (pancreas,
papilla, distal bile duct) tumor is associated with a higher risk of postoperative complications than
in non-jaundiced patients. Preoperative biliary drainage was introduced in an attempt to improve
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BMC Surgery 2007, 7:3 http://www.biomedcentral.com/1471-2482/7/3the general condition and thus reduce postoperative morbidity and mortality. Early studies showed
a reduction in morbidity. However, more recently the focus has shifted towards the negative
effects of drainage, such as an increase of infectious complications. Whether biliary drainage should
always be performed in jaundiced patients remains controversial. The randomized controlled
multicenter DROP-trial (DRainage vs. Operation) was conceived to compare the outcome of a
'preoperative biliary drainage strategy' (standard strategy) with that of an 'early-surgery' strategy,
with respect to the incidence of severe complications (primary-outcome measure), hospital stay,
number of invasive diagnostic tests, costs, and quality of life.
Methods/design: Patients with obstructive jaundice due to a periampullary tumor, eligible for
exploration after staging with CT scan, and scheduled to undergo a "curative" resection, will be
randomized to either "early surgical treatment" (within one week) or "preoperative biliary
drainage" (for 4 weeks) and subsequent surgical treatment (standard treatment). Primary outcome
measure is the percentage of severe complications up to 90 days after surgery. The sample size
calculation is based on the equivalence design for the primary outcome measure. If equivalence is
found, the comparison of the secondary outcomes will be essential in selecting the preferred
strategy. Based on a 40% complication rate for early surgical treatment and 48% for preoperative
drainage, equivalence is taken to be demonstrated if the percentage of severe complications with
early surgical treatment is not more than 10% higher compared to standard treatment:
preoperative biliary drainage. Accounting for a 10% dropout, 105 patients are needed in each arm
resulting in a study population of 210 (alpha = 0.95, beta = 0.8).
Discussion: The DROP-trial is a randomized controlled multicenter trial that will provide
evidence whether or not preoperative biliary drainage is to be performed in patients with
obstructive jaundice due to a periampullary tumor.
Background
Patients with obstructive jaundice caused by a tumor in
the pancreatic head area (pancreas, distal bile duct,
papilla of Vater), without radiological evidence of irre-
sectability, will undergo an exploration with the intention
of resection of the tumor, being the only option for cure
[1-4]. If a resection is not possible due to locoregional irre-
sectability or distant metastases, a biliary and gastric
bypass procedure is performed [5-8]. Surgery in jaundiced
patients with a tumor in the pancreatic head area is asso-
ciated with a higher risk of postoperative complications
compared with surgery in non jaundiced patients [9-11].
These complications primarily consist of septic complica-
tions (cholangitis, abscesses, and leakage), haemorrhage,
impaired wound healing and renal disorders. The
increased risk of surgery in jaundiced patients was recog-
nized already in 1935 by Allen O. Whipple, who proposed
a two staged procedure for surgery in deeply jaundiced
patients. The first stage consisted of a drainage procedure
by a cholecystogastrostomy, to decompress the biliary
tract in order to restore normal liver function, followed
four weeks later by radical resection of the tumor [12].
Numerous experimental and clinical studies have been
performed since, investigating the cause and directed at
prevention of complications after surgery in patients with
obstructive jaundice.
While the postoperative mortality rate after pancreatodu-
odenectomy has been reduced from around 20% to 1–5%
in experienced centres, the morbidity rate has remained
virtually unchanged, ranging from 40 to 60% [5,6,8,9].
Many different etiologic factors for development of com-
plications have been characterized: presence of toxic sub-
stances as bilirubin and bile salts, impaired nutritional
status, effects of endotoxins, bacterial translocation, mod-
ulation of the inflammatory cascade with cytokine release,
reduction of cellular immunity and nutritional status [13-
21]. For these etiologic factors different interventions have
been undertaken in the past decades, attempting to lower
the risk of complications. The current project addresses
the issue of preoperative biliary drainage (PBD).
Early studies on external PBD could not demonstrate a
reduction in complication rate in humans because this
procedure, although relieving the biliary obstruction,
does not restore the bile flow to the gut lumen [22]. Inter-
nal drainage has been shown in multiple experimental
models to improve liver function and nutritional status,
to reduce systemic endotoxemia and cytokine release, and
subsequently to improve immune response [13-15,19-
21]. Finally the mortality was significantly reduced in
these animal models[16]. The first non-randomized stud-
ies on internal PBD in jaundiced patients reported a
reduced mortality and morbidity [22]. However, clinical
studies and small randomized trials could not confirm thePage 2 of 9
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studies even reported a deleterious effect, partly due to
complications associated with the drainage procedure
[28-32]. Despite these results, PBD is generally accepted in
The Netherlands. In previous studies we found that
around 90% of patients with obstructive jaundice cur-
rently undergo preoperative drainage in The Netherlands
[28,29]. The dominance of drainage can be attributed in
part to the familiarity of endoscopic retrograde cholangi-
opancreatography (ERCP), which has been used in the
past as the first diagnostic procedure for obstructive jaun-
dice. The time needed for extensive diagnostic workup,
including diagnostic laparoscopy (DL), is a logistic expla-
nation for the assumed benefit of PBD. However, the
value of DL for periampullary tumors is disputed, espe-
cially in the light of improvement of other non-invasive
diagnostic procedures [1-4,33,34]. Other important fac-
tors that influence the decision to opt for PBD are (local)
referral patterns and waiting lists. Current state-of-the-art
radiological diagnostic and staging procedures for sus-
pected periampullary tumors require only a minimum of
time [1]. These non-invasive radiological procedures have
the same diagnostic accuracy as ERCP, an invasive diag-
nostic procedure, and, moreover, offer the advantage of
assessing local tumor extension as well as distant metas-
tases [1-3]. Therefore, ERCP with subsequent drainage as
part of a routine diagnostic workup is outdated.
ERCP and endoscopic sphincterotomy with insertion of
biliary and pancreatic stents is a difficult gastrointestinal
endoscopic procedure. Complications, such as haemor-
rhage, pancreatitis, perforation of the duodenal wall,
cholangitis and stent occlusion cannot always be avoided
and occur in approximately 10 percent of procedures
[35,36]. Mortality as a consequence of the procedure is
reported in 0.5%–1% of the cases [36]. The negative side-
effects of PBD, such as an increase of infectious complica-
tions after surgery, has been the focus of attention in more
recent studies [30-32]. It was concluded that the potential
advantages of preoperative drainage fail to outweigh the
negative effects [20,23,24,28-32].
In the light of the ongoing controversy of PBD, a meta-
analysis of randomized clinical trials and comparative
studies was carried out [37]. The aim of this study was to
evaluate the efficacy of drainage in jaundiced patients
compared with patients that underwent direct surgical
treatment. No difference in mortality could be detected
between both strategies, but overall complication rate in
patients that underwent PBD was significantly higher
compared with direct surgical treatment, 57.3% and
41.9% respectively (level I evidence). The mean overall
hospital stay was increased by two weeks in patients that
underwent biliary drainage. Unfortunately, most of the
studies have methodological flaws (e.g. differences in
drainage procedures, duration of drainage, internal vs.
external drainage, surgical procedures, small sample size)
and do not provide unequivocal treatment recommenda-
tions. Therefore, a prospective randomized trial address-
ing the effects of PBD is indicated. Especially, for the
potential consequences of future treatment might be con-
siderable; a shorter workup period, less invasive diagnos-
tic procedures (ERCP) and a shorter time interval to
surgery. The study focuses on complication rate (40–
60%), the primary endpoint for most past studies.
Methods/Design
Study objectives
The proposed project involves a randomized multicenter
trial to compare the outcome of "a preoperative biliary
drainage strategy" (standard strategy) with that of an
"early surgery" strategy, with respect to the incidence of
severe complications (primary outcome measure), hospi-
tal stay, number of invasive diagnostic tests and costs.
Study design
The DROP-trial is a randomized multicenter trial with
four academic and ten regional hospitals participating in
the project. Patients with obstructive jaundice (bilirubin
level 40–250 µmol/l) due to a pancreatic/periampullary
tumor, who are candidate for exploration after staging
with CT scan, and scheduled to undergo a "curative" resec-
tion, will be randomized to either "early surgical treat-
ment" (within one week) or "preoperative biliary
drainage" (for four weeks) and subsequent surgical treat-
ment (standard treatment) (figure 1). Randomization is
centralized in the Academic Medical Center, Amsterdam,
by means of a computer generated allocation with stratifi-
cation for center.
Study population
The study population consists of patients with the clinical
diagnosis of obstructive jaundice due to a pancreatic head
or periampullary tumor. Inclusion criteria are; a serum
bilirubin level of > 40 µmol/l and < 250 µmol/l at rand-
omization, CT without evidence of distant metastases or
local tumor ingrowth into portal or mesenteric vessels (as
defined by the tumor surrounding the vessel for at least
180 degrees of the circumference), referred for surgical
treatment to one of the participating centres, time
between CT and randomization ≤ 4 days, informed con-
sent. Exclusion criteria are; age > 85 years or severe co-
morbidity (Karnofsky <50%) and other contraindications
for major surgery, cholangitis/infection, previous ERCP
and stenting or percutaneous biliary drainage, previous
chemotherapy for this malignancy, severe gastric outlet
obstruction (stenosis duodenum due to tumor ingrowth)
defined as vomiting, nausea and/or oral intake less than
one l/day.Page 3 of 9
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DROP-study flowchartFigure 1
DROP-study flowchart.
BMC Surgery 2007, 7:3 http://www.biomedcentral.com/1471-2482/7/3Primary outcome parameter
Primary outcome parameter are severe complications and
the study is designed for detecting equivalence in the
occurrence of these events during treatment within 120
days after randomization. This will include at least 90
days follow-up after surgery, a period selected as ade-
quate, while > 95% of complications will occur within 30
days after surgery. A longer observation period up to one
year will potentially include effects of progressive or recur-
rent disease.
A severe complication is defined as any complication,
related to the drainage procedure and surgical treatment,
leading to an additional invasive intervention or
relaparotomy with subsequent prolonged hospital stay or
death, or readmission for disease related morbidity within
120 days after randomization (table 1). The definition of
all these complications, as well as their management, have
been extensively evaluated in previous studies in our insti-
tution during the past 10 years according to generally
accepted criteria [5,28,29,35,36,38,39].
To exclude bias in determining events of the primary end-
point, a blinded adjunction committee will review all
events and evaluate whether events account as severe
complications (with intervention, relaparotomy) needing
prolonged hospital stay, or even a readmission.
Secondary outcome parameters
Secondary endpoints are hospital stay, the number of
(invasive) diagnostic procedures, medical and non medi-
cal costs, and quality of life. Quality of life will be meas-
ured for patients treated at the trial centre, at fixed
intervals, by two validated questionnaires; the European
Organisation for Research and Treatment of Cancer
(EORTC) Quality of Life Questionnaire C-30 (QLQ-C30)
and its Pancreatic Cancer Module (QLQ-PAN26) [40].
Participating centres
Fourteen Dutch hospitals of the DROP-Trial group,
including four academic centres and ten non-academic
centres, are currently participating in this trial.
Ethics
This study is conducted in accordance with the principles
of the Declaration of Helsinki and 'good clinical practice'
guidelines. The independent medical ethics committees
of the participating hospitals have approved the study
protocol. Prior to randomization, written informed con-
sent will be obtained from all patients.
Table 1: Severe ERCP- and surgery-related (postoperative) complications [5,28,29,35,36,38,39,43,44].
COMPLICATION CRITERIA
ERCP
- Acute pancreatitis Abdominal pain and a serum concentration of pancreatic enzymes (amylase or lipase) two or 
more times the upper limit of normal, that required more than one night of hospitalisation
- Cholangitis Elevation in the temperature to more than 38°C, thought to have a biliary cause, without 
concomitant evidence of acute cholecystitis
- Acute cholecystitis No suggestive clinical or radiographic signs of acute cholecystitis before the procedure and if 
emergency cholecystectomy is subsequently required
- Perforation Retroperitoneal or bowel-wall perforation documented by any radiographic technique
- Haemorrhage Clinical evidence of bleeding (melena or hematemesis) with an associated decrease of at least 
2 g per decilitre in the haemoglobin concentration, or the need for a blood transfusion
- Stent Occlusion Recurring obstructive jaundice with necessary stent replacement
SURGERY
- Pancreatojejunostomy leakage Drain output of any measurable volume of fluid on or after postoperative day 3 with an 
amylase content greater than 3 times the serum amylase activity, graded according to clinical 
course (ISGPS grade A, B, C)
- Postpancreatectomy haemorrhage Bleeding after the index operation requiring ≥ 4 units of packed cells and/or leading to 
relaparotomy/intervention
- Delayed gastric emptying Gastric stasis requiring nasogastric intubation for 10 days or more, or the inability to tolerate 
a regular (solid) diet on or before the fourteenth postoperative day
- Biliary leakage Bilirubin in abdominal drain or dehiscence found at laparotomy
- Sepsis Presence of two or more of the following: fever or hypothermia, leucocytosis or leucopenia, 
tachycardia, and tachypnea or a supernormal minute ventilation
- Intra-abdominal abscess formation Intra-abdominal fluid collection with positive cultures identified by ultrasonography or 
computed tomography, associated with persistent fever and elevations of white blood cells
- Wound infection Requiring intervention with subsequent prolonged hospital stay, otherwise considered as 
minor complication
- Burst abdomen
- Any relaparotomy for other reasons
- PneumoniaPage 5 of 9
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Patients may be included if CT scan has demonstrated a
lesion in the pancreatic head area without metastases and/
or local tumor ingrowth. Local physicians/gastroenterolo-
gists can refer patients for the study by contacting the pri-
mary trial centre or one of the participating centres (see
addendum 1). Written informed consent will be obtained
at the outpatient department according to the Guidelines
of Clinical Research in Humans, when the patient meets
the in- and exclusion criteria. Randomization is per-
formed instantly by the trial centre.
After randomization, patients will be scheduled, either for
surgical treatment within one week, or PBD with subse-
quent surgical treatment after four weeks. PBD is prefera-
bly performed by local gastroenterologists or in the
referral centre according to local policy. The participating
centres accepted to arrange extra operating room capacity
to guarantee early surgery to be carried out when indi-
cated.
ERCP + PBD
- ERCP with stent placement will be performed by an
experienced endoscopist, by insertion of a single (plastic)
stent
- If ERCP is not successful, the patient is to be referred to
a tertiary centre for a second attempt for endoscopic drain-
age, or a percutaneous drainage will be performed,
according to local preference and expertise.
- Biliary drainage is considered adequate if a decrease of >
50% of serum bilirubin level is found after two weeks of
drainage; otherwise the stent should be changed.
- After four weeks of PBD, patients will undergo surgery.
In case of complications indicating inadequate bile drain-
age and stent obstruction (cholangitis, stent occlusion) a
stent exchange will be performed.
- Other complications, such as bleeding or severe pancre-
atitis, are treated according to the local generally accepted
guidelines and could consequently lead to a delay of sur-
gery [35,36].
- Preoperative nutritional support (e.g. consultation with
a dietician) is recommended in patients with a weight loss
of more than 15% during the last 3 months.
Surgery
- Surgery is planned keeping in mind the maximum esti-
mated bilirubin level (> 40 µmol/l and < 250 µmol/l at
randomization) must not exceed 300 µmol/l, 24 hours
before surgery (e.g. high bilirubin at randomization
requires earlier surgery).
- Vitamin K (10 mg, oral, 1 day preoperatively) is given on
indication, cefuroxim (1500 mg, intravenous single shot,
1/2 hour preoperatively) and octreotide or analogues (3 ×
100 µg, subcutaneous, 12 hours before surgery and con-
tinued for seven days after surgery) as prophylaxis.
- During exploration the standard procedure will be the
standard pylorus preserving pancreatoduodenectomy
(PPPD), as previously described, with removal of lymph
nodes at the right side of the portal vein [33]. If indicated
(suspicious ingrowth proximal duodenum/pylorus) a
Whipple procedure is to be performed. In case of limited
vascular ingrowth, a (wedge) resection of the portal/
mesenteric vein might be performed [33,41].
- Reconstruction is performed by pancreaticojejunostomy,
a hepaticojejunostomy and gastrojejunostomy [33].
- One silicone drain is placed near the pancreaticojejunos-
tomy and/or one near the hepaticojejunostomy; T-drains
will not be used.
- A feeding jejunostomy is not to be used as standard treat-
ment
- If resection is not performed due to metastases or local
ingrowth, biopsies have to be taken for a histological diag-
nosis.
Palliative treatment consist of a hepaticojejunostomy
with gastroenterostomy plus a celiac plexus blockade
[7,33,42]. If a hepaticojejunostomy is not possible, a
Wallstent is inserted postoperatively by means of ERCP.
Statistical analysis
Intention to treat
The analysis will be performed in accordance with the
intention to treat principle.
Sample size calculation
The recently performed meta-analysis of randomized clin-
ical trials and comparative studies, addressing the effec-
tiveness of a PBD strategy in jaundiced patients versus a
direct surgical treatment, did not show a difference in
mortality between the two strategies [37]. The overall
complication rates were, summarizing level I and II stud-
ies, 42% for the 'early surgery' strategy and 58.1% for strat-
egy with preceding PBD.
The sample size calculation is based on the equivalence
design for the primary endpoint, severe complications of
treatment. Based on an expected 38% complication rate
for early surgical treatment and 48% for preoperative
drainage, equivalence is taken to be demonstrated if the
percentage of severe complications with early surgicalPage 6 of 9
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standard treatment with PBD. Accounting for a 10% drop-
out, 105 patients are needed in each arm resulting in a
study population of 210 (alpha = 0.95, beta = 0.8). If
equivalence is found, the comparison of the secondary
outcomes will be essential in selecting the preferred strat-
egy.
Data collection and monitoring
All postoperative complications will be monitored during
hospital stay and follow-up of 2, 6, 12 weeks after dis-
charge. The questionnaires (QLQ-C30/PAN-26) are filled
in by the patient on the day of randomization, after two
weeks of drainage when randomized for PBD, and three
and six weeks after discharge from admission for surgery.
There will be regular contact between the trial coordinator
and the participating centres. The trial coordinator will
monitor the data of every included patient.
Data analysis
The study is designed as an equivalence trial with respect
to the primary outcome measure and superiority with
respect to the secondary outcome measures. The principal
analysis consists of an intention-to-treat comparison of
the severe complication rate in both treatment strategies.
The comparison will be expressed in terms of a relative
risk and 95% confidence intervals. The research hypothe-
sis will be evaluated using a two-group large-sample nor-
mal approximation test of proportions, with a one-sided
0.05 significance level. In addition, a comparison of the
incidence of complications over time will be made using
Kaplan-Meier estimates.
Subsequent analyses are directed at the secondary end-
points. The total number of additional procedures, the
length of hospital stay, hospital-free survival and total
costs will be compared using t-test statistics. Preplanned
subgroup analyses include type of surgery (resection ver-
sus bypass), severity of jaundice and other risk factors for
complications such as age > 70 years, weight loss > 10%,
low albumin levels, renal function, low Hb (< 7 mmol/l),
tumor pathology (papilla neoplasms, pancreatic head
neoplasms and distal bile duct neoplasms).
An independent safety committee, consisting of three spe-
cialists (dept of internal medicine, dept of surgery, dept of
clinical statistics), will guarantee the safety of the patients.
After 105 included patients (50%), a blinded interim-
analysis will be performed of all endpoints. Because of the
delayed response for determination of the primary end-
point (severe complications), this analysis will be per-
formed 120 days after randomization of the last patient to
reach n: 105. The nominal significance (sequential two-
sided testing) for the stopping rule is p < 0.01 (α = 0.01)
for adverse effects (severe complications principal end-
point of safety analysis). Analysis will be performed for
the individual groups and for the principal adverse effects.
Economic evaluation
If the assumption of equivalence holds, the economic
evaluation can be designed as a cost-minimization analy-
sis from a societal perspective. Given equivalence in sur-
vival for the two strategies, the time horizon for the
evaluation can be limited to 120 days after randomiza-
tion.
According to guidelines for cost research, the two treat-
ment strategies will be compared from the societal per-
spective, regarding direct medical and non-medical and
indirect non-medical costs. In the economic evaluation
direct medical and non-medical costs and indirect costs
are related to the primary endpoints, reflecting economic
efficiency at 3 months after admission.
We expect early surgery without preoperative biliary
drainage to lead to a shorter hospital stay, less invasive
diagnostic tests, fewer additional procedures and, hence,
lower costs. Nowadays overall mortality after PD is
around 2% for control patients (drainage) and therefore
an increase or reduction of mortality can only have lim-
ited influence on the primary outcome parameter (severe
complications and death). As we could not find any data
to provide even an indication of economic outcomes of
both strategies, the evaluation will be designed as a cost-
effectiveness analysis.
To document cumulative three-month total costs for both
treatment strategies, we will track the use of resources,
using hospital information systems and additional data
collection in the case record forms. The tracking of
resources will start at randomization (i.e. after preopera-
tive staging has been completed). Unit prices will either be
determined based on current guidelines for economic
evaluations or, alternatively, if not existent or not applica-
ble, they will be calculated during the study. Out of hos-
pital resource use, as well as data on direct non-medical
and indirect costs will not be analyzed. Within the study,
differences in treatment will be analyzed to detect poten-
tial limitations to the reproducibility of our findings.
Discussion
The concept of PBD has been developed to reduce the
postoperative morbidity and mortality in patients with
obstructive jaundice, caused by a suspected pancreatic/
periampullary malignancy. However, PBD, both endo-
scopic or percutaneous, is associated with an increased
incidence of postoperative morbidity [mostly infectious
complications] and postoperative mortality when per-
formed prior to a pancreatoduodenectomy. Furthermore,
the techniques used for PBD harbour their own complica-Page 7 of 9
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perform preoperative biliary drainage seems evident. Nev-
ertheless, still the majority of these patients undergo pre-
operative drainage, often preceded by a diagnostic
endoscopic retrograde cholangiopancreatography
(ERCP). Unfortunately, most of the available literature
addressing the efficacy of PBD suffers from methodologi-
cal flaws (e.g. differences in drainage procedures, duration
of drainage, internal vs. external drainage, surgical proce-
dures, small sample size) or is outdated.
Therefore, a prospective randomized trial addressing the
effects of PBD, and thus solving the longstanding contro-
versy whether or not PBD should be routinely performed
in jaundiced patients prior to a pancreatoduodenectomy,
is indicated. Especially, for the potential consequences of
future treatment might be considerable; a shorter workup
period, less invasive diagnostic procedures (ERCP) and a
shorter time interval to surgery.
Abbreviations
DROP-trial: DRainage vs. (direct) Operation
PBD: preoperative biliary drainage
ERCP: endoscopic retrograde cholangiopancreatography
EORTC QLQ-C30: European Organisation for Research
and Treatment of Cancer (EORTC) Quality of Life Ques-
tionnaire C-30
EORTC QLQ-PAN26: European Organisation for
Research and Treatment of Cancer (EORTC) Quality of
Life Questionnaire PANcreas-26
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
NAvdG and SMMC drafted the manuscript. DJG is the
principal investigator of this study and co-authored the
writing of the manuscript. PMMB, OMD, CHJE, EJK,
JJGMG, JWG, EJH, JHGK, CJHML, LTW, MJB EAJW partic-
ipated in the design of the study during several meetings
and are local investigators at the participating centres. The
other authors are local investigators. All authors edited the
manuscript and read and approved the final manuscript.
Acknowledgements
ZonMw, grant number 945-03-015
All authors are member of the DROP-study group.
References
1. Guidelines for the management of patients with pancreatic
cancer periampullary and ampullary carcinomas.  Gut 2005,
54 Suppl 5:v1-16.
2. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM:
Biliary tract cancers.  N Engl J Med 1999, 341:1368-1378.
3. Phoa SS, Reeders JW, Rauws EA, De WL, Gouma DJ, Lameris JS: Spi-
ral computed tomography for preoperative staging of poten-
tially resectable carcinoma of the pancreatic head.  Br J Surg
1999, 86:789-794.
4. Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP,
Sharp KW, Richards WO, Wright JK, Frexes ME, Pinson CW, Leach
SD: 18Fluorodeoxyglucose-positron emission tomography in
the management of patients with suspected pancreatic can-
cer.  Ann Surg 1999, 229:729-737.
5. Gouma DJ, van Geenen RC, van Gulik TM, de Haan RJ, de Wit LT,
Busch OR, Obertop H: Rates of complications and death after
pancreaticoduodenectomy: risk factors and the impact of
hospital volume.  Ann Surg 2000, 232:786-795.
6. Balcom JH, Rattner DW, Warshaw AL, Chang Y, Fernandez-del CC:
Ten-year experience with 733 pancreatic resections: chang-
ing indications, older patients, and decreasing length of hos-
pitalization.  Arch Surg 2001, 136:391-398.
7. van Heek NT, de Castro SM, van Eijck CH, van Geenen RC, Hesselink
EJ, Breslau PJ, Tran TC, Kazemier G, Visser MR, Busch OR, Obertop
H, Gouma DJ: The need for a prophylactic gastrojejunostomy
for unresectable periampullary cancer: a prospective rand-
omized multicenter trial with special focus on assessment of
quality of life.  Ann Surg 2003, 238:894-902.
8. van Wagensveld BA, Coene PP, van Gulik TM, Rauws EA, Obertop H,
Gouma DJ: Outcome of palliative biliary and gastric bypass
surgery for pancreatic head carcinoma in 126 patients.  Br J
Surg 1997, 84:1402-1406.
9. Pitt HA, Cameron JL, Postier RG, Gadacz TR: Factors affecting
mortality in biliary tract surgery.  Am J Surg 1981, 141:66-72.
10. Armstrong CP, Dixon JM, Taylor TV, Davies GC: Surgical experi-
ence of deeply jaundiced patients with bile duct obstruction.
Br J Surg 1984, 71:234-238.
11. Greig JD, Krukowski ZH, Matheson NA: Surgical morbidity and
mortality in one hundred and twenty-nine patients with
obstructive jaundice.  Br J Surg 1988, 75:216-219.
12. Whipple AO, Parsons WB, Mullins CR: Treatment of carcinoma
of the ampulla of Vater.  Ann Surg 1935, 102:763-779.
13. Gouma DJ, Coelho JC, Fisher JD, Schlegel JF, Li YF, Moody FG: Endo-
toxemia after relief of biliary obstruction by internal and
external drainage in rats.  Am J Surg 1986, 151:476-479.
14. Roughneen PT, Gouma DJ, Kulkarni AD, Fanslow WF, Rowlands BJ:
Impaired specific cell-mediated immunity in experimental
biliary obstruction and its reversibility by internal biliary
drainage.  J Surg Res 1986, 41:113-125.
15. Gouma DJ, Roughneen PT, Kumar S, Moody FG, Rowlands BJ:
Changes in nutritional status associated with obstructive
jaundice and biliary drainage in rats.  Am J Clin Nutr 1986,
44:362-369.
16. Gouma DJ, Coelho JC, Schlegel JF, Li YF, Moody FG: The effect of
preoperative internal and external biliary drainage on mor-
tality of jaundiced rats.  Arch Surg 1987, 122:731-734.
17. Greve JW, Gouma DJ, Buurman WA: Bile acids inhibit endotoxin-
induced release of tumor necrosis factor by monocytes: an in
vitro study.  Hepatology 1989, 10:454-458.
18. Greve JW, Gouma DJ, von Leeuwen PA, Buurman WA: Lactulose
inhibits endotoxin induced tumour necrosis factor produc-
tion by monocytes. An in vitro study.  Gut 1990, 31:198-203.
19. Greve JW, Gouma DJ, Soeters PB, Buurman WA: Suppression of
cellular immunity in obstructive jaundice is caused by endo-
toxins: a study with germ-free rats.  Gastroenterology 1990,
98:478-485.
20. Bemelmans MH, Gouma DJ, Greve JW, Buurman WA: Cytokines
tumor necrosis factor and interleukin-6 in experimental bil-
iary obstruction in mice.  Hepatology 1992, 15:1132-1136.
21. Bemelmans MH, Gouma DJ, Greve JW, Buurman WA: Effect of
antitumour necrosis factor treatment on circulating tumour
necrosis factor levels and mortality after surgery in jaun-
diced mice.  Br J Surg 1993, 80:1055-1058.Page 8 of 9
(page number not for citation purposes)
BMC Surgery 2007, 7:3 http://www.biomedcentral.com/1471-2482/7/3Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
22. Gouma DJ, Moody FG: Preoperative percutaneous transhe-
patic drainage: use or abuse. A clinical review.  Surg Gastroen-
terol 1984, 3:74-80.
23. McPherson GA, Benjamin IS, Hodgson HJ, Bowley NB, Allison DJ,
Blumgart LH: Pre-operative percutaneous transhepatic biliary
drainage: the results of a controlled trial.  Br J Surg 1984,
71:371-375.
24. Pitt HA, Gomes AS, Lois JF, Mann LL, Deutsch LS, Longmire WP Jr.:
Does preoperative percutaneous biliary drainage reduce
operative risk or increase hospital cost?  Ann Surg 1985,
201:545-553.
25. Hatfield AR, Tobias R, Terblanche J, Girdwood AH, Fataar S, Harries-
Jones R, Kernoff L, Marks IN: Preoperative external biliary
drainage in obstructive jaundice. A prospective controlled
clinical trial.  Lancet 1982, 2:896-899.
26. Lai EC, Mok FP, Fan ST, Lo CM, Chu KM, Liu CL, Wong J: Preoper-
ative endoscopic drainage for malignant obstructive jaun-
dice.  Br J Surg 1994, 81:1195-1198.
27. Smith RC, Pooley M, George CR, Faithful GR: Preoperative percu-
taneous transhepatic internal drainage in obstructive jaun-
dice: a randomized, controlled trial examining renal
function.  Surgery 1985, 97:641-648.
28. Karsten TM, Allema JH, Reinders M, van Gulik TM, de Wit LT, Ver-
beek PC, Huibregtse K, Tytgat GN, Gouma DJ: Preoperative bil-
iary drainage, colonisation of bile and postoperative
complications in patients with tumours of the pancreatic
head: a retrospective analysis of 241 consecutive patients.
Eur J Surg 1996, 162:881-888.
29. Sewnath ME, Birjmohun RS, Rauws EA, Huibregtse K, Obertop H,
Gouma DJ: The effect of preoperative biliary drainage on
postoperative complications after pancreaticoduodenec-
tomy.  J Am Coll Surg 2001, 192:726-734.
30. Sohn TA, Yeo CJ, Cameron JL, Pitt HA, Lillemoe KD: Do preoper-
ative biliary stents increase postpancreaticoduodenectomy
complications?  J Gastrointest Surg 2000, 4:258-267.
31. Povoski SP, Karpeh MS Jr., Conlon KC, Blumgart LH, Brennan MF:
Association of preoperative biliary drainage with postopera-
tive outcome following pancreaticoduodenectomy.  Ann Surg
1999, 230:131-142.
32. Lillemoe KD: Preoperative biliary drainage and surgical out-
come.  Ann Surg 1999, 230:143-144.
33. Gouma DJ, Nieveen van Dijkum EJ, Obertop H: The standard diag-
nostic work-up and surgical treatment of pancreatic head
tumours.  Eur J Surg Oncol 1999, 25:113-123.
34. Nieveen van Dijkum EJ, Romijn MG, Terwee CB, de Wit LT, van der
Meulen JH, Lameris HS, Rauws EA, Obertop H, van Eyck CH, Bossuyt
PM, Gouma DJ: Laparoscopic staging and subsequent pallia-
tion in patients with peripancreatic carcinoma.  Ann Surg 2003,
237:66-73.
35. Huibregtse K: Complications of endoscopic sphincterotomy
and their prevention.  N Engl J Med 1996, 335:961-963.
36. Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC,
Liguory C, Nickl N: Endoscopic sphincterotomy complications
and their management: an attempt at consensus.  Gastrointest
Endosc 1991, 37:383-393.
37. Sewnath ME, Karsten TM, Prins MH, Rauws EJ, Obertop H, Gouma
DJ: A meta-analysis on the efficacy of preoperative biliary
drainage for tumors causing obstructive jaundice.  Ann Surg
2002, 236:17-27.
38. van Berge Henegouwen MI, van Gulik TM, Akkermans LM, Jansen JB,
Gouma DJ: The effect of octreotide on gastric emptying at a
dosage used to prevent complications after pancreatic sur-
gery: a randomised, placebo controlled study in volunteers.
Gut 1997, 41:758-762.
39. Kimmings AN, Van Deventer SJ, Obertop H, Rauws EA, Huibregtse
K, Gouma DJ: Endotoxin, cytokines, and endotoxin binding
proteins in obstructive jaundice and after preoperative bil-
iary drainage.  Gut 2000, 46:725-731.
40. Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA, Bassi
C, Beger HG, Birk D, Buchler MW, Dervenis C, Fernandez CL, Friess
H, Grahm AL, Jeekel J, Laugier R, Meyer D, Singer MW, Tihanyi T:
Development of a disease specific quality of life (QoL) ques-
tionnaire module to supplement the EORTC core cancer
QoL questionnaire, the QLQ-C30 in patients with pancreatic
cancer. EORTC Study Group on Quality of Life.  Eur J Cancer
1999, 35:939-941.
41. Allema JH, Reinders ME, van Gulik TM, Van Leeuwen DJ, de Wit LT,
Verbeek PC, Gouma DJ: Portal vein resection in patients under-
going pancreatoduodenectomy for carcinoma of the pancre-
atic head.  Br J Surg 1994, 81:1642-1646.
42. Lillemoe KD, Cameron JL, Kaufman HS, Yeo CJ, Pitt HA, Sauter PK:
Chemical splanchnicectomy in patients with unresectable
pancreatic cancer. A prospective randomized trial.  Ann Surg
1993, 217:447-455.
43. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, Neop-
tolemos J, Sarr M, Traverso W, Buchler M: Postoperative pancre-
atic fistula: an international study group (ISGPF) definition.
Surgery 2005, 138:8-13.
44. de Castro SM, Kuhlmann KF, Busch OR, van Delden OM, Lameris JS,
van Gulik TM, Obertop H, Gouma DJ: Delayed massive hemor-
rhage after pancreatic and biliary surgery: embolization or
surgery?  Ann Surg 2005, 241:85-91.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2482/7/3/prepubPage 9 of 9
(page number not for citation purposes)
